Standard BioTools (LAB) Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
January 9, 2023 8:30 AM ESTContinued commercial and strategic execution delivers sequential core revenue growth of 4%9% to $26 million$27 million in Q4 2022 for full year total of approximately $94 million$95 million
Business restructuring and SBS program on track to deliver over 20% reduction in operating expenses or more than $30 million and reduces annual operating expenses to approximately $100 million exiting Q4. GAAP operating expense reductions are expected to be over 25% and over $35 million.
On track for achieving stated goal of 65%68% non-GAAP gross margins by the end of 2023. GAAP... More
